NPCE
Neuropace Inc
$
8.980
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.125
Open
9.020
VWAP
8.95
Vol
374.47K
Mkt Cap
294.53M
Low
8.790
Amount
3.35M
EV/EBITDA(TTM)
--
Total Shares
28.77M
EV
288.06M
EV/OCF(TTM)
--
P/S(TTM)
3.19
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
24.81M
+15.57%
-0.193
+7.46%
24.31M
+15.42%
-0.190
+0.08%
23.08M
+19.88%
-0.217
-16.5%
Estimates Revision
The market is revising Upward the revenue expectations for NeuroPace, Inc. (NPCE) for FY2025, with the revenue forecasts being adjusted by 1.07% over the past three months. During the same period, the stock price has changed by -22.72%.
Revenue Estimates for FY2025
Revise Upward
+1.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+5.63%
In Past 3 Month
Stock Price
Go Down
-22.72%
In Past 3 Month
7 Analyst Rating
96.77% Upside
Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is 17.67 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
96.77% Upside
Current: 8.980
Low
16.00
Averages
17.67
High
20.00
96.77% Upside
Current: 8.980
Low
16.00
Averages
17.67
High
20.00
H.C. Wainwright
initiated
$18
2025-05-28
Reason
H.C. Wainwright
Price Target
$18
2025-05-28
initiated
Reason
H.C. Wainwright initiated coverage of NeuroPace with a Buy rating and $18 price target. NeuroPace is a commercial-stage medical device company focused on the development and marketing of a brain-responsive neuromodulation system that can deliver personalized, real-time treatment at the seizure source for patients with drug-resistant focal epilepsy, the analyst tells investors in a research note. The firm says the cutback after the one-year data readout from the NAUTILUS study presents an attractive entry point, as the data have no impact on the sales momentum in patients with focal epilepsy.
JPMorgan
Overweight
maintain
$14 -> $16
2025-05-13
Reason
JPMorgan
Price Target
$14 -> $16
2025-05-13
maintain
Overweight
Reason
JPMorgan raised the firm's price target on NeuroPace to $16 from $14 and keeps an Overweight rating on the shares. The company reported good Q1 results ahead of the Street, with gross margin and revenue topping estimates and operating expense coming in lower, the analyst tells investors in a research note. This was another strong quarter for NeuroPace, with healthy contribution from Project Care, record new prescribers, and sustained utilization across Level 4 centers, the firm added.
Cantor Fitzgerald
Ross Osborn
Buy
Maintains
$19 → $20
2025-03-05
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$19 → $20
2025-03-05
Maintains
Buy
Reason
Wells Fargo
Larry Biegelsen
Buy
Maintains
$13 → $17
2025-01-30
Reason
Wells Fargo
Larry Biegelsen
Price Target
$13 → $17
2025-01-30
Maintains
Buy
Reason
Wells Fargo raised the firm's price target on NeuroPace to $17 from $13 and keeps an Overweight rating on the shares. The firm notes NeuroPace laid out its strategy and LRP at its investor day on January 28. Wells views its new multiple as appropriate given solid management execution and recent beat and raises.
UBS
Priya Sachdeva
Strong Buy
Initiates
$17
2025-01-21
Reason
UBS
Priya Sachdeva
Price Target
$17
2025-01-21
Initiates
Strong Buy
Reason
JP Morgan
Robbie Marcus
Buy
Maintains
$9 → $14
2024-12-17
Reason
JP Morgan
Robbie Marcus
Price Target
$9 → $14
2024-12-17
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Neuropace Inc (NPCE.O) is -11.99, compared to its 5-year average forward P/E of -8.19. For a more detailed relative valuation and DCF analysis to assess Neuropace Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.19
Current PE
-11.99
Overvalued PE
-2.48
Undervalued PE
-13.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-12.31
Current EV/EBITDA
-18.18
Overvalued EV/EBITDA
-1.68
Undervalued EV/EBITDA
-22.94
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
4.14
Current PS
3.04
Overvalued PS
6.90
Undervalued PS
1.39
Financials
Annual
Quarterly
FY2025Q1
YoY :
+24.28%
22.52M
Total Revenue
FY2025Q1
YoY :
-31.78%
-5.15M
Operating Profit
FY2025Q1
YoY :
-26.17%
-6.59M
Net Income after Tax
FY2025Q1
YoY :
-34.38%
-0.21
EPS - Diluted
FY2025Q1
YoY :
-1.48%
-7.52M
Free Cash Flow
FY2025Q1
YoY :
+4.58%
76.99
Gross Profit Margin - %
FY2025Q1
YoY :
-15.90%
-21.52
FCF Margin - %
FY2025Q1
YoY :
-40.60%
-29.25
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.7M
USD
1
3-6
Months
50.6M
USD
2
6-9
Months
52.5K
USD
3
0-12
Months
1.9M
USD
29
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
175.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.7M
USD
1
3-6
Months
50.6M
USD
2
6-9
Months
52.5K
USD
3
0-12
Months
1.9M
USD
29
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NPCE News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
16:19:02
NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed
2025-06-17 (ET)
2025-06-17
09:10:44
Femasys appoints Nicholas as CCO
2025-05-27 (ET)
2025-05-27
10:56:40
Leerink says NeuroPace results disappointing, sees hope on totality of data
Sign Up For More Events
Sign Up For More Events
News
7.0
07-06GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
7.0
06-28GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
5.0
06-24NewsfilterNeuroPace Announces Strategic CFO Transition
Sign Up For More News
People Also Watch
RBB
RBB Bancorp
18.950
USD
-0.79%
QUAD
Quad/Graphics Inc
5.850
USD
+1.21%
TITN
Titan Machinery Inc
20.120
USD
+1.56%
VLN
Valens Semiconductor Ltd
3.120
USD
0.00%
CNL
Collective Mining Ltd
9.370
USD
-0.21%
SAR
Saratoga Investment Corp
25.190
USD
-0.59%
ZVIA
Zevia PBC
3.290
USD
-2.95%
DADA
Dada Nexus Ltd
0
USD
-1.28%
NECB
Northeast Community Bancorp Inc
22.500
USD
+0.90%
RIGL
Rigel Pharmaceuticals Inc
20.170
USD
-1.27%
FAQ
What is Neuropace Inc (NPCE) stock price today?
The current price of NPCE is 8.98 USD — it has decreased -0.99 % in the last trading day.
What is Neuropace Inc (NPCE)'s business?
What is the price predicton of NPCE Stock?
What is Neuropace Inc (NPCE)'s revenue for the last quarter?
What is Neuropace Inc (NPCE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Neuropace Inc (NPCE)'s fundamentals?
How many employees does Neuropace Inc (NPCE). have?